Temedica builds an ecosystem that combines health-related data from registries, sales, insurance, patient experience sources and, with explicit consent, patient-generated app data to produce actionable insights. The company processes more than 40 billion data points across over 50,000 diagnoses to derive insights on disease progression, treatment effectiveness, patient journeys, and medication adherence. Its insights are intended to serve patients, health care professionals, clinics, research institutions, pharma and biotech companies, and pharmacies. Led by CEO and founder Gloria Seibert, Temedica’s mission is to enable personalized and individualized medicine by focusing on patients and their individual needs. The company says it processes data in compliance with the GDPR. Temedica plans to use the new funding to accelerate expansion of its ecosystem and to advance its development efforts. Temedica builds a bundle of certified digital health apps for the German market, including Pelvina (pelvic‑floor training), Mineo (back training) and Waya (weight‑loss). Many of its apps are offered free to users through certifications and agreements with most German health insurers, and the company holds contracts with individual insurers. Public insurers had awaited confirmation from the central inspection agency that the apps are effective in preventive health. The startup intends to internationalise its products and will research differing regulatory frameworks across countries. The new funding is earmarked to scale the product suite and grow the team from about 40 employees to roughly 100 by year‑end.

Total raised

$45M

Funding rounds

2

Latest round

Series B

Latest activity

Nov 2022